

POSTERS

[Clinical](#)

[Non-clinical](#)

Clinical

P-1

ADJUVANT EFFECT OF IV CLODRONATE ON DELAY OF BONE METASTASIS IN HIGH-RISK PROSTATE CANCER PATIENTS. A PROSPECTIVE STUDY

P Rodrigues^[1,2], F Hering^[1,2]

^[1]Urology, Hospital 9 de Julho of São Paulo, São Paulo, Brazil; ^[2]Urology, Hospital Santa Helena of São Paulo, São Paulo, Brazil

P-2

SURGICAL RESECTION OF ISOLATED BREAST CANCER RECURRENCE WITHIN THE STERNUM

J Crighton, P Hall, S Lord, T Perrin, D Dodwell

St James Institute of Oncology, Leeds Teaching Hospitals, Leeds, UK

P-3

AN OBSERVATIONAL PROSPECTIVE COHORT STUDY ON THE DOSE EFFECT OF ZOLEDRONIC ACID ON URINARY N-TELOPEPTIDE LEVELS IN METASTATIC PROSTATE CANCER

L Drudge-Coates^[1], C Brown^[1], R Sherwood^[2], PM Thompson^[1], GH Muir^[1]

^[1]Dept of Urology, King's College Hospital NHS Foundation Trust, London, UK; ^[2]Dept of Clinical Biochemistry, King's College Hospital NHS Foundation Trust, London, UK

P-4

A MULTICENTER PROSPECTIVE STUDY OF THE RISK FACTORS AFFECTING BONE MINERAL DENSITY IN KOREAN PATIENTS WITH PROSTATE CANCER

SI Jung^[1], SO Kim^[1], TW Kang^[1], DD Kwon^[1], JY Park^[2], J Cheon^[3], HM Lee^[4], SJ Hong^[5], HY Choi^[4], SB Ryu^[1]

^[1]Urology, Chonnam National University, Gwangju, Korea; ^[2]Urology, University of Ulsan, Seoul, Korea; ^[3]Urology, Korea University, Seoul, Korea; ^[4]Urology, Sungkyunkwan University, Seoul, Korea; ^[5]Urology, Yonsei University, Seoul, Korea

P-5

NATURAL HISTORY OF MALIGNANT BONE DISEASE IN COLORECTAL CANCER: FINAL RESULTS OF A LARGE ITALIAN "BONE METASTASES" SURVEY

D Santini^[1], S Barni^[2], M Tampellini^[3], N Silvestris^[4], E Maiello^[5], N Calipari^[6], T Ibrahim^[7], V Catalano^[8], B Vincenzi^[1], G Tonini^[1]

^[1]Oncology, University Campus Bio-Medico, Rome, Italy; ^[2]Oncology, Azienda Ospedaliera Treviglio-Caravaggio, Treviglio (MI), Italy; ^[3]Oncology, University of Torino at San Luigi Hospital, Orbassano (TO), Italy; ^[4]Oncology, Oncology Institute Giovanni Paolo II, Bari, Italy; ^[5]Oncology, IRCCS Casa Sollievo della Sofferenza, S Giovanni Rotondo (FG), Italy; ^[6]Oncology, Ospedali Riuniti, Reggio Calabria, Italy; ^[7]Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (FC), Italy; ^[8]Oncology, A. O. San Salvatore, Pesaro, Italy

P-6

EFFICACY OF ZOLEDRONIC ACID IN PATIENTS WITH COLORECTAL CANCER METASTATIC TO BONE

D Santini^[1], F Loupakis^[2], R Berardi^[3], G Badalamenti^[4], L Addeo^[5], C Ortega^[6], R Sabbatini^[7], O Venditti^[1], V Virzi^[1], B Vincenzi^[1], G Tonini^[1]

^[1]Medical Oncology, University Campus Bio-Medico, Rome; ^[2]Medical Oncology, Department of Oncology, Transplants and New Technologies in Medicine, University of Pisa, Pisa; ^[3]Medical Oncology, Clinica di Oncologia Medica, AO Ospedali Riuniti, Università Politecnica delle Marche, Ancona; ^[4]Department of Surgery and Oncology, University of Palermo, Palermo; ^[5]Department of Oncology, San Giovanni Di Dio Hospital, Frattaminore, Naples; ^[6]University Division of Medical Oncology and Haematology, Institute for Cancer Research and Treatment (IRCC), Candiolo; ^[7]Medical Oncology, Università degli Studi di Modena e Reggio Emilia

P-7

THE ITALIAN CROSS-SECTIONAL SURVEY ON THE MANAGEMENT OF BONE HEALTH IN ONCOLOGY: THE ZETA STUDY (ON BEHALF OF ZETA STUDY GROUP)

F Bertoldo^[1], D Santini^[2], I Cecchini^[3], P Bartolussi^[3], S Fregosi^[3]

^[1]Dept of Medicine, University of Verona, Italy; ^[2]Oncologia Medica, University Campus Biomedico, Rome, Italy; ^[3]GfK Eurisko, Milan, Italy

P-8

ONE YEAR EFFECT OF ANASTROZOLE AND RISEDRONATE ON BONE MINERAL DENSITY: FIRST RESULTS FROM THE IBIS-II BONE SUB-STUDY

S Singh^[1], J Cuzick^[1], G M Blake^[2], D Mesher^[1], R Patel^[3], J Truscott^[4], R Coleman^[5], A Howell^[6], J Forbes^[7], R Eastell^[8]

^[1]Cancer Research UK Centre for Epidemiology, Mathematics and Statistics, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK; ^[2]Osteoporosis Research Unit, Division of Imaging Sciences, King's College London, London, UK; ^[3]Academic Bone Densitometry Unit, Imperial College London, London, UK; ^[4]Academic Unit of Medical Physics, University of Leeds, Leeds, UK; ^[5]Academic Unit of Clinical Oncology, Cancer Research Centre, Weston Park Hospital, Sheffield, UK; ^[6]Nightingale and Genesis Prevention Centre, University Hospital of South Manchester, Manchester, UK; ^[7]Department of Surgical Oncology, Newcastle Mater Hospital, University of Newcastle, Newcastle, Australia; ^[8]Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, UK

P-9

IS THERE ANY SCOPE FOR THE USE OF ARSENIC TRIOXIDE (ATO) IN THE TREATMENT OF RELAPSED MYELOMA (MM)?

N Tajeja^[1], J Nagi^[2]

^[1]Department of Internal Medicine, Wayne State University/DMC, Detroit, MI; ^[2]Division of Hematology, Providence Hospital, Detroit, MI

P-10

RELATIONSHIP BETWEEN SERUM N-TELOPEPTIDE AND BONE ALKALINE PHOSPHATASE AND THEIR DIAGNOSTIC VALUE IN PATIENTS WITH BREAST CANCER AND BONE METASTASES

F Lumachi^[1], V Camozzi^[2], G Luisetto^[2], R Orlando^[2], SMM Basso^[3], U Basso^[4], P Cappelletti^[5]

^[1]Department of Surgical and Gastroenterological Sciences, University of Padua, School of Medicine, 35128 Padova, Italy; ^[2]Department of Medical and Surgical Sciences, University of Padua, School of Medicine, 35128 Padova, Italy; ^[3]UO Chirurgia I, S. Maria degli Angeli Hospital, 33170 Pordenone, Italy; ^[4]Istituto Oncologico Veneto (IOV) IRCCS, 35128 Padova, Italy; ^[5]General Management, Centro Oncologico Regionale (CRO) IRCCS, 33081 Aviano (PN), Italy

P-11

EXPERIMENTAL STUDY OF SPECIFIC ANTITUMOR IMMUNITY INDUCED BY DENDRITIC CELL VACCINE TRANSFECTED WITH TUMOR CELL TOTAL RNA IN EWING SARCOMA PATIENTS

HX SANG, Jian WANG, Lin WANG, Zhen WANG, Bin LU, Yong FAN, WJ ZHU

Department of Orthopaedic Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China

P-12

EXPRESSION OF MATRIX METALLOPROTEINASE 1 (MMP1) AND DICKKOPF-1 (DKK1) IN BONE METASTATIC TISSUE (BMT) AND IN SERUM OF PATIENTS WITH BONE METASTASES (BM) FROM DIFFERENT SOLID TUMORS

L Costa^[1], I Luís^[1], I Alho^[1], A Fernandes^[1], S Casimiro^[1], B.H Lee^[2], E.A Gangolli^[2], M Motwani^[2], L Wang^[2], V Modur^[2]

^[1]Oncology, Hospital de Santa Maria - Instituto de Medicina Molecular, Lisbon, Portugal; ^[2]Oncology Biomarkers and Clinical Imaging, Novartis Institutes for Biomedical Research, Cambridge, USA

P-13

REDUCED RISK OF BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS. PRELIMINARY RESULTS IN A HIGH RISK METROPOLITAN AREA: A CASE-CONTROL STUDY

F Lumachi^[1], V Tombolan^[2], V Camozzi^[3], G Luisetto^[3], SMM Basso^[4], A Brunello^[5], U Basso^[5]

^[1]Department of Surgical and Gastroenterological Sciences, University of Padua, School of Medicine, 35128 Padova, Italy; ^[2]University of Padua, School of Medicine, 35128 Padova, Italy; ^[3]Department of Medical and Surgical Sciences, University of Padua, School of Medicine, 35128 Padova, Italy; ^[4]UO Chirurgia 1, S. Maria degli Angeli Hospital, 33170 Pordenone, Italy; ^[5]Istituto Oncologico Veneto (IOV) IRCCS, 35128 Padova, Italy

P-14

EXPLOITING THE TEAR PROTEOME FOR THE DIAGNOSIS OF BREAST CANCER

C Washam^[1], S Byrum^[1], S Bhattacharyya^[1], VS Klimberg^[2,3], LJ Suva^[1,3]

^[1]Orthopaedic Surgery, Center for Orthopaedic Research, UAMS, Little Rock, AR, USA; ^[2]Departments of Surgery, and Pathology, UAMS, Little Rock, AR, USA; ^[3]Breast Cancer Program, UAMS, Little Rock, AR, USA

P-15

BONE MINERAL DENSITY AND BONE REMODELLING MARKERS OSTEOCALCIN AND ALKALINE PHOSPHATASE IN PATIENTS WITH STAGE IV BREAST CANCER

F Lumachi^[1], V Camozzi^[2], G Luisetto^[2], R Orlando^[2], SMM Basso^[3], A Brunello^[4], U Basso^[4]

^[1]Department of Surgical and Gastroenterological Sciences, University of Padua, School of Medicine, 35128 Padova, Italy; ^[2]Department of Medical and Surgical Sciences, University of Padua, School of Medicine, 35128 Padova, Italy ; ^[3]UO Chirurgia 1, S. Maria degli Angeli Hospital, 33170 Pordenone, Italy; ^[4]Istituto Oncologico Veneto (IOV) IRCCS, 35128 Padova, Italy

P-16

CAN BONE BIOPSIES BE USED TO CONFIRM METASTATIC DISEASE RECURRENCE AND RECEPTOR STATUS IN BREAST CANCER PATIENTS?

E Amir^[1], N Miller^[2], W Geddie^[2], H Maung^[1], OC Freedman^[1], M Oldfield^[1], J Napolskikh^[1], F Kassam^[1], M Clemons^[3]

^[1]Division of Medical Oncology, Princess Margaret Hospital, Toronto, Canada; ^[2]Department of Pathology, University Health Network, Toronto, Canada; ^[3]Division of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, Canada

P-17

HYPOCALCEMIA IN MULTIPLE MYELOMA SECONDARY TO UNRECOGNISED VITAMIN D DEFICIENCY: A CASE REPORT

I Ramasamy

Dept of Chemical Pathology, Worcester Royal Hospital, Worcester, UK

P-18

RAPID PAIN REDUCTION FOLLOWING LOADING-DOSE IBANDRONATE IN BONE METASTASES

AA Kurth^[1], A Müller^[2], B Habermann^[1], C Eberhardt^[3]

^[1]Orthopaedic Surgery, University Medical Center, Mainz, Germany; ^[2], Outpatient Cancer Center, Frankfurt, Germany; ^[3]Orthopaedic Surgery, Klinikum, Hanau, Germany

P-19

PROSPECTIVE CLINICAL TRIAL TO EVALUATE THE VALUE OF RADIOFREQUENCY ABLATION AND CEMENT AUGMENTATION OF SPINAL METASTASES

D Proschek, B Habermann, M Tonak, P Proschek, AA Kurth

Department of Orthopaedic Surgery, University Medical Center, Mainz, Germany

P-20

CLINICAL RESULTS AND THE MECHANISM OF BONE HEALING FOR THE REPAIR OF BONE DEFECTS DUE TO TUMOR RESECTION WITH NOVEL INTERPOROUS TRICALCIUM PHOSPHATE

HX SANG^[1], zhen WANG^[1], Lin WANG^[1], Zheng GUO^[1], JX LU^[2], Yong FAN^[1]

^[1]Department of Orthopaedic Surgery, Xijing Hospital, Forth Military Medical University, Xi'an 710032 P.R. China; ^[2]Institute of Biomaterial and Biotechnology of the Littoral University, 62608 Berck sur Mer, France

P-21

METASTATIC BONE DISEASE OF THE MANDIBLE - A CASE REPORT

B Drozdowska^[1], A Raczkowska-Siostrzonek^[2], R Koszowski^[2]

^[1]Dept of Pathology, Medical University of Silesia, Zabrze, Poland; ^[2]Dept of Oral Surgery, Medical University of Silesia, Bytom, Poland

P-22

BONE HEALTH IN BREAST CANCER SURVIVORS FOLLOWING ADJUVANT BISPHOSPHONATE THERAPY: AZURE QUANTITATIVE BONE SCAN SUB-STUDY

EJ Woodward^[1,2], JE Brown^[1,2], MC Barnfield^[3], J Taylor^[4], GM Blake^[5], I Fogelman^[5], LA Turner^[2], H Thorpe^[6], D Dodwell^[3], JK Joffe^[7], RE Coleman^[2]

^[1]CRUK Clinical Centre and Leeds Institute of Molecular Medicine, University of Leeds, Leeds, UK;

^[2]Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield, UK; ^[3]St. James' Institute of Oncology, Leeds Teaching Hospitals Trust, Leeds, UK; ^[4]Royal Hallamshire Hospital, Sheffield Teaching Hospitals Trust, Sheffield, UK; ^[5]School of Medicine, King's College London, London, UK; ^[6]Clinical Trials Research Unit, University of Leeds, Leeds, UK; ^[7]Huddersfield Royal Infirmary, Calderdale and Huddersfield NHS Foundation Trust, Huddersfield, UK

P-23

SAFETY OF ZOLEDRONIC ACID AND INCIDENCE OF OSTEONECROSIS OF THE JAW (ONJ) DURING ADJUVANT THERAPY IN A RANDOMISED PHASE III TRIAL (AZURE – BIG 01-04) FOR WOMEN WITH STAGE II/III BREAST CANCER

RE Coleman^[1], EJ Woodward^[1,2], JE Brown^[1,2], D Cameron^[2,3], R Bell^[4], D Dodwell^[2], M Keane^[5], M Gil^[6], C Davies^[7], R Burkinshaw^[1], SJ Houston^[8], RJ Grieve^[9], PJ Barrett-Lee^[10], H Thorpe^[7]

^[1]Academic Unit of Clinical Oncology, Weston Park Hospital, University of Sheffield, UK; ^[2]St James Institute of Oncology, University of Leeds, UK; ^[3]Western General Hospital, University of Edinburgh, UK; ^[4]Andrew Love Cancer Centre, Geelong, Australia; ^[5]University Hospital Galway, Ireland; ^[6]Institut Català d'Oncologia – IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain on behalf of SOLTI Group; ^[7]Clinical Trials Research Unit, University of Leeds, Leeds, UK; ^[8]St Lukes Cancer Centre, Royal Surrey County Hospital, Guildford, UK; ^[9]University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK; ^[10]Velindre Cancer Center, Whitechurch, Cardiff, UK

P-24

GENE EXPRESSION IN PROSTATE CANCER BONE METASTASES IN RELATION TO EXPRESSION OF THE ANDROGEN RECEPTOR AND ONE OF ITS CONSTITUTIVELY ACTIVE VARIANTS

E Hörnberg^[1], A Bergh^[1], A Widmark^[2], H Antti^[3], P Wikström^[1]
^[1]Medical Biosciences, Pathology, Umeå University, Umeå, Sweden; ^[2]Radiation Sciences, Oncology, Umeå University, Umeå, Sweden; ^[3]Chemistry, Umeå University, Umeå, Sweden

P-25

ANALYSIS OF THE VARIOUS COMPONENTS OF BONE TURNOVER IN
POSTMENOPAUSAL BREAST CANCER PATIENTS WITH BONE METASTASES

F Bertoldo, S Pancheri, S Boldini, S Zenari, A Avesani

Biomedical and Surgical Sciences Department, University of Verona, Verona, Italy

P-26

THE ADDITION OF ZOLEDRONIC ACID TO COMBINATION CHEMOTHERAPY
DECREASES CIRCULATING SERUM LEVELS OF VASCULAR ENDOTHELIAL GROWTH
FACTOR (VEGF) IN EARLY BREAST CANCER

M.C. Winter, A. Evans, I. Holen, R.E. Coleman

Academic Unit of Clinical Oncology, University of Sheffield, Sheffield, U.K

P-27

COMPARING EARLY INTERVENTION WITH ZOLEDRONIC ACID TO NO
BISPHOSPHONATE (BP) THERAPY IN PATIENTS WITH METASTATIC PROSTATE
CANCER TO BONE: A STUDY OF THE US VETERANS AFFAIRS (VA) POPULATION

EQ Wu^[1], A Guo^[2], L Shi^[3], M Lu^[1], AP Yu^[1], H Sharma^[1], CPS Fan^[1], N Vander Velde^[4]

^[1]None, Analysis Group, Inc, Boston, MA, USA; ^[2]Health Economics and Outcomes Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; ^[3]Health System Management, Tulane University, New Orleans, LA, USA; ^[4]School of Medicine, Hematology and Medical Oncology Section, Tulane University, New Orleans, LA, USA

P-28

THE ROLE OF PAMIDRONATE IN PALLIATIVE TREATMENT FOR BONE METASTASES IN
SQUAMOUS CELL CARCINOMA OF HEAD AND NECK

W Rolski^[1], W Leppert^[2]

^[1]Head and Neck Cancer Department, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; ^[2]Chair and Department of Palliative Medicine, Poznan University of Medical Sciences, Poznan, Poland

P-29

PTH 1-84: RESULTS AFTER 18 MONTH OF THERAPY IN WOMEN WITH SEVERE POST-
MENOPAUSAL OSTEOPOROSIS

R Pastore^[1], D Mentuccia^[1], P Borboni^[2], L Chioma^[2], G Vancieri^[2], P Di Giacinto^[2], G V Frajese^[3]

^[1]UOC Endocrinologia, Ospedale Fatebenefratelli, Isola Tiberina, Roma, Italy; ^[2]Dipartimento di Medicina Interna, Università di Tor Vergata, Roma, Italy; ^[3]Facoltà di Scienze Motorie e della Salute, Università degli Studi di Cassino, Cassino (Frosinone), Italy

Non-clinical

P-30

LYMPHANGIOGENESIS IN PAPILLARY THYROID CANCER: NO CORRELATION
BETWEEN LYMPHATIC MICROVESSEL DENSITY AND AGE, TUMOR SIZE, TOTAL
LYMPH NODE AND METASTASES NUMBERS IN A COHORT OF 18 PEDIATRIC PATIENTS

MV Sprindzuk

Biomedical image analysis laboratory, National Academy of Sciences, Minsk, Belarus

P-31

GLUTAMATE RELEASE IN BONE METASTASIS

EP Seidlitz^[1,2], MK Sharma^[1,2], G Singh^[1,2]

^[1]Pathology & Molecular Medicine, McMaster University, Hamilton, Ontario, Canada; ^[2]Research, Juravinski Cancer Centre, Hamilton, Ontario, Canada

P-32

THE CHEMOKINE RECEPTOR CXCR7 IS HIGHLY EXPRESSED IN BONE METASTATIC LESIONS OF HUMAN PROSTATE CANCER AND MEDIATES TUMOR CELL GROWTH AND INVASIVENESS IN PRECLINICAL MODELS

GL Gravina^[1, 2], M Angelini^[3], R Montironi^[4], L Ventura^[5], F Marampon^[1,2], G Pratesi^[6], M Tortoreto^[6], V Tombolini^[2], C Festuccia^[1]

^[1]Department of Experimental Medicine, ^[1]Laboratory of Radiotherapy, University of L'Aquila, L'Aquila, Italy; ^[2]Department of Experimental Medicine, Division of Radiotherapy, University of L'Aquila, L'Aquila, Italy; ^[3]Department of Experimental Medicine, General Pathology, University of L'Aquila, L'Aquila, Italy; ^[4]Pathology Division, Neuroscience Department, Univerisità Politecnica delle Marche, Ancona, Italy; ^[5]Pathology Division, San Salvatore Hospital, L'Aquila, Italy; ^[6]Molecular Cytogenetics Unit, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milano, Italy

P-33

CCN3 IMPAIRS OSTEOBLASTS AND STIMULATES OSTEOCLAST DIFFERENTIATION TO FAVOR BREAST CANCER METASTASIS TO BONE

E Amir^[1], V Ouellet^[2], A Mourskaia^[2], K Tiedemann^[3], J Fong^[3], D Tran-Tanh^[1], M Clemons^[1], B Perbal^[4], S Komorova^[3], P Siegel^[2]

^[1]Medical Oncology, Princess Margaret Hospital, Toronto, Canada; ^[2]The Goodman Cancer Research Centre, McGill University, Montreal, Canada; ^[3]The Faculty of Dentistry, McGill University, Montreal, Canada; ^[4]Research and Development, L'Oreal USA, New Jersey, USA

P-34

AMG 161, A FULLY HUMAN MONOCLONAL ANTIBODY TO HUMAN RANKL, INHIBITS TUMOR-INDUCED OSTEOCLASTOGENESIS AND REDUCES SKELETAL TUMOR BURDEN IN MICE THAT EXPRESS CHIMERIC (MURINE / HUMAN) RANKL

JR Canon^[1], R Bryant^[1], M Roudier^[2], A Coxon^[1], WC Dougall^[3]

^[1]Oncology Research, Amgen, Inc., Thousand Oaks, CA, USA; ^[2]Pathology, Amgen, Inc., Seattle, WA, USA; ^[3]Oncology Research, Amgen, Inc., Seattle, WA, USA

P-35

ACTIVATION OF THE OSTEOPONTIN GENE, A BONE METASTATIC SIGNATURE, BY TRANSCRIPTION FACTOR ERG IN PROSTATIC CANCER CELLS

S Flajollet^[1], TV Tian^[1], A Flourens^[1], N Tomavo^[1], E Bonnelye^[2], X Leroy^[3], M Duterque-Coquillaud^[1]

^[1]CNRS UMR8161, Institut de Biologie de Lille, CNRS/Université de Lille Nord de France/Institut Pasteur de Lille, Lille, France; ^[2]Unité INSERM U664, INSERM/Faculté de Médecine Laënnec/Université Claude Bernard Lyon 1, Lyon, France; ^[3]Tumor tissue Bank CRRC/ Canceropole Nord-Ouest (CNO), Pôle de Pathologie, Centre de Biologie-Pathologie, Lille, France

P-36

TOWARDS BIOMARKERS OF BONE-METASTASIS USING CELLULAR PROTEOMICS

JA Westbrook^[1], J Peng^[1], DA Cairns^[1], PD Ottewell^[2], I Holen^[2], RE Coleman^[2], PJ Selby^[1], RE Banks^[1], JE Brown^[1]

^[1]Cancer Research UK Clinical Centre, St James's University Hospital, Leeds, UK; ^[2]Department of Oncology, The Medical School, Sheffield, UK

P-37

A STUDY OF THE ROLE OF TWIST IN MIGRATION AND INVASION OF BREAST CANCER CELLS

S Li^[1], SE Kendall^[1,2], R Raices^[1], C Tran^[1], Z Liu^[3], M Covarrubias^[3], VK Leigh^[1], SD Flanagan^[1], CA Glackin^[1]

^[1]Neurosciences, Beckman Reserach Institute, Duarte, California, USA; ^[2]Graduate School , Beckman Reserach Institute, Duarte, California, USA; ^[3]Bioinformatics, Beckman Reserach Institute, Duarte, California, USA

P-38

CAMP-RESPONSE-ELEMENT-BINDING PROTEIN POSITIVELY REGULATES BREAST CANCER METASTASIS AND SUBSEQUENT BONE DESTRUCTION

J Son, JH Lee, HN Kim, H Ha, ZH Lee

Department of Cell and Developmental Biology, Seoul National University School of Dentistry, Seoul, South Korea

P-39

OSTEOPROTEGERIN INHIBITITS BONE RESORPTION AND PREVENTS TUMOR DEVELOPMENT IN A XENOGENIC MODEL OF EWING'S SARCOMA BY INHIBITING RANKL PRODUCED BY TUMOR CELLS

G Picarda, E Matous, S Hervouet, F Lamoureux, V Trichet, D Heymann, F Rédini

UMR 957 - EA 3822, INSERM - Université de nantes, Nantes, France

P-40

RANKL SILENCING BY SIRNA IMPROVES THERAPEUTIC RESPONSE OF PRIMARY OSTEOSARCOMA TO CONVENTIONAL CHEMOTHERAPY

J Rousseau^[1, 2], V Escriou^[3], F Lamoureux^[1, 2], R Brion^[1, 2], S Battaglia^[1, 2], D Scherman^[3], D Heymann^[1, 2], F Rédini^[1, 2], V Trichet^[1, 2]

^[1]U957, INSERM, Nantes, France; ^[2]EA3822, University, Nantes, France; ^[3]U640, INSERM, Paris, France

P-41

OSTEOLYTIC VERSUS MIXED OSTEOLYTIC/OSTEOBLASTIC VERTEBRAL METASTASIS: COMPARISON OF BONE STRUCTURAL AND REMODELLING PROPERTIES IN TWO PRECLINICAL RAT MODELS

L Wise-Milestone^[1], MK Akens^[1], NK Thudi^[2], TJ Rosol^[2], MD Grynepas^[3], A Yee^[1], B Wilson^[4], CM Whyne^[1]

^[1]Orthopaedic Biomechanics Lab, Sunnybrook Health Sciences Centre, Toronto, Canada;

^[2]Veterinary Biosciences, The Ohio State University, Columbus, United States; ^[3]Laboratory

Medicine and Pathobiology, Samuel Lunenfeld Research Institute, Toronto, Canada; ^[4]Biophysics and Imaging, Ontario Cancer Institute, Toronto, Canada

P-42

LOCAL TREATMENT OF MIXED OSTEOLYTIC/OSTEOBLASTIC SPINAL METASTASES: IS PHOTODYNAMIC THERAPY EFFECTIVE?

L Wise-Milestone^[1], MK Akens^[1], NK Thudi^[2], TJ Rosol^[2], MD Grynepas^[3], A Yee^[1], B Wilson^[4], CM Whyne^[1]

^[1]Orthopaedic Biomechanics Lab, Sunnybrook Health Sciences Centre, Toronto, Canada;

^[2]Veterinary Biosciences, The Ohio State University, Columbus, United States; ^[3]Laboratory

Medicine and Pathobiology, Samuel Lunenfeld Research Institute, Toronto, Canada; ^[4]Biophysics and Imaging, Ontario Cancer Institute, Toronto, Canada

P-43

INFLUENCE OF PRE-TREATMENT WITH BISPHOSPHONATE ON THE OUTCOME OF PHOTODYNAMIC THERAPY ON BREAST CANCER METASTASES IN MURINE VERTEBRAE

MK Akens^[1,2], L Wise-Milestone^[1], E Won^[1], BC Wilson^[3], AJM Yee^[1,2], CM Whyne^[1,2]

^[1]Orthopaedic Biomechanics Laboratory, Sunnybrook Health Sciences Centre, Toronto, Canada; ^[2]Department of Surgery, University of Toronto, Toronto, Canada; ^[3]Ontario Cancer Institute, University Health Network, Toronto, Canada

P-44

DIRECT ANTI-CANCER EFFECT OF ONCOSTATINE M ON CHONDROSARCOMA

E David^[1], P Guihard^[1], B Brounais^[1], A Riet^[1], C Charrier^[1], S Battaglia^[1], S Ponsolle^[2], R Le Bot^[3], CD Richards^[4], D Heymann^[1], F Redini^[1], F Blanchard^[1]

^[1]U957, INSERM, Nantes, France; ^[2]UTCG, CHU de Nantes, Nantes, France; ^[3]Atlantic Bone Screen, ABS, Nantes, France; ^[4]Center for gene therapeutics, McMaster University, Hamilton, Canada

P-45

CONTROLLED SKELETAL TISSUE ABLATION USING NOVEL NAVIGATIONAL RADIO FREQUENCY ABLATION DEVICE

AA Kurth^[1], D Proschek^[1], A Germain^[2], R Poser^[2]

^[1]Department of Orthopaedic Surgery, University Medical Center, Mainz, Germany; ^[2]DFine Inc., San Jose, USA

P-46

THE NOVEL ANTI-RESORPTIVE AGENT REVEROMYCIN A AMELIORATES BONE DESTRUCTION AND TUMOR GROWTH IN MYELOMA

K Watanabe^[1], M Abe^[2], C Qu^[2], M Kawatani^[3], M Hiasa^[4], A Nakano^[2], T Harada^[2], S Nakamura^[2], H Miki^[2], K Kagawa^[2], K Takeuchi^[2], H Ozaki^[5], H Osada^[3], E Tanaka^[6], T Matsumoto^[2]

^[1]Orthodontics and Dentofacial Orthopedics, The University of Tokushima Graduate School of Oral Sciences, Tokushima, Japan; ^[2]Medicine and Bioregulatory Sciences, The University of Tokushima Graduate School of Medicine, Tokushima, Japan; ^[3]Chemical Biology Core Facility, RIKEN Advanced Science Institute, Wako, Japan; ^[4]Biomaterials and Bioengineering, The University of Tokushima Graduate School of Oral Sciences, Tokushima, Japan; ^[5]Transfusion Medicine, Tokushima University Hospital, Tokushima, Japan; ^[6]Orthodontics and Dentofacial Orthopedics, Institute of Health Biosciences, Tokushima, Japan

P-47

MECHANISMS OF OSTEOBLAST SUPPRESSION IN MULTIPLE MYELOMA

D Kassen^[1], N Rabin^[1], D Lath^[2], PI Croucher^[2], K Yong^[1]

^[1]Department of Haematology, UCL Cancer Institute, London, UK; ^[2]Academic Unit of Bone Biology, University of Sheffield, Sheffield, UK

P-48

TARGETING TCF TRANSCRIPTIONAL ACTIVITY RESCUES SYNDECAN-2 EXPRESSION AND RE-SENSITIZES HUMAN OSTEOSARCOMA CELLS AND MOUSE BONE TUMOURS TO DOXORUBICIN

FX Dieudonné, A Marion, PJ Marie, D Modrowski
U606, INSERM, PARIS, FRANCE

P-49

ABNORMAL EXPRESSION OF CALPAIN-6 DUE TO ENDOTHELIN-1/NFKB SIGNALLING CONTRIBUTES TO CELL SURVIVAL AND CHEMORESISTANCE IN OSTEOSARCOMA CELLS

A Marion^[1], FX Dieudonné^[1], A Patiño^[2], F Lecanda^[2], PJ Marie^[1], D Modrowski^[1]

^[1]U606, INSERM, Paris, France; ^[2]Center for Applied Medical Research, University of Navarra, Pamplona, Spain

P-50

TWO-DIMENSIONAL AND THREE-DIMENSIONAL CULTURE OF HUMAN BONE MARROW STROMAL CELLS WITH DIFFERENT SCAFFOLDS

HX SANG^[1], PP LIN^[2], Wei MU^[1], GC LI^[1], Lin WANG^[1], ZX WU^[1], Yong FAN^[1], ZS MA^[1], Wei LEI^[1], GX PEI^[1]

^[1]Department of Orthopaedic Surgery, Xijing Hospital, Forth Military Medical University, Xi'an 710032, China; ^[2]Department of Orthopaedic Oncology, University of Texas M.D. Anderson Cancer Center, Houston TX 77030, USA

P-51

NOVEL APPLICATION OF APTAMER SELECTION (PHENO-SELEX) TO TARGET THE INVASIVE PHENOTYPE SUCCESSFULLY CREATES ANTI-METASTATIC APTAMERS

G Shelley, X Zhang, J Keller, E Keller

Urology Surgery, University of Michigan, Ann Arbor, USA

P-52

ACCELERATED OSTEOLYTIC METASTASIS IN B16-INOCULATED MICE PRE-EXPOSED TO NON-SKELETAL FOCAL IRRADIATION IN THE ABDOMEN

Q Fu^[1], L Hennings^[2], D Gaddy^[3], PM Corry^[1], D Jia^[1]

^[1]Radiation Oncology, University of Arkansas for Medical Sciences, Little Rock, USA; ^[2]Pathology, University of Arkansas for Medical Sciences, Little Rock, USA; ^[3]Physiology, University of Arkansas for Medical Sciences, Little Rock, USA

P-53

SKELETAL RIGIDITY ENHANCES TGF-B EFFECTS ON CANCER CELL EXPRESSION OF OSTEOLYTIC FACTORS

NS Ruppender^[1,2], JA Sterling^[2,3], TJ Martin^[2,4], GR Mundy^[2,3,5], SA Guelcher^[1,2,5]

^[1]Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, USA; ^[2]Center for Bone Biology, Vanderbilt University, Nashville, USA; ^[3]Cancer Biology, Vanderbilt University, Nashville, USA; ^[4]Bone Cell Biology, University of Melbourne, Melbourne, Australia; ^[5]Orthopaedics, Vanderbilt University, Nashville, USA

P-54

EXAMINATION OF THE MECHANISM(S) OF CANCER-INDUCED BONE PAIN IN ANIMAL MODELS

R Ungard^[1], E Seidlitz^[1], P De Ciantis^[1], K Yashpal^[2], JL Henry^[2], G Singh^[1]

^[1]Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada; ^[2]Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada

P-55

INTERACTION OF AUTOTAXIN WITH BREAST CANCER CELL INTEGRINS MIGHT CONTRIBUTE TO LYSOPHOSPHATIDIC ACID-MEDIATED BONE METASTASES

M David^[1,2,3], R Leblanc^[1,2,3], B Deux^[1,2,3], CM Serre^[1,2,3], J Ribeiro^[1,2,3], P Clézardin^[1,2,3], O Peyruchaud^[1,2,3]

^[1]Unit 664, INSERM, Lyon cedex 08, France; ^[2] Université Claude Bernard Lyon 1, Lyon, France; ^[3] Faculté de Médecine Laennec, Lyon, France

P-56

A DIRECT CONTACT MODEL SYSTEM TO STUDY TUMOR CELL-BONE CELL INTERACTIONS IN PROSTATE CANCER BONE METASTASES

A Nordstrand^[1], P Wikström^[2], UH Lerner^[3], A Widmark^[1]

^[1]Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden; ^[2]Department of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden; ^[3]Department of Oral Cell Biology, Umeå University, Umeå, Sweden

P-57

COMPARISON OF OPTICAL, RADIOGRAPHY AND MICRO COMPUTED TOMOGRAPHY IMAGING METHODS FOR THE ANALYSIS OF BONE METASTASES IN A MURINE MODEL
S Tiwari^[1], C Schem^[2], AC Lorenzen^[2], O Kayser^[1], C Graeff^[1], J Peña^[1], RP Marshall^[3], W Jonat^[2], CC Glüer^[2]

^[1]Medical Physics, Department of Diagnostic Radiology, University Hospital Schleswig-Holstein, Kiel, Germany; ^[2]Department of Gynecology, University Hospital Schleswig-Holstein, Kiel, Germany; ^[3]Institute for Osteology and Biomechanics, University Hospital Eppendorf, Hamburg, Germany

P-58

CHANGES IN OSTEOBLAST AND OSTEOCLAST NUMBER RELY ON DIRECT CONTACT WITH BREAST CANCER CELLS – EVIDENCE FROM A LONGITUDINAL STUDY OF BONE METASTASIS

HK Brown, PD Ottewell, CA Evans, I Holen
Oncology, University of Sheffield, Sheffield, UK

P-59

MOLECULAR CHARACTERIZATION OF THE STROMAL RESPONSE TO OSTEOBLASTIC BONE METASTASIS BY TISSUE-COMPARTMENT SPECIFIC TRANSCRIPTIONAL PROFILING

B Ozdemir^[1], C Secondini^[1], A Wetterwald^[1], R Schwaninger^[1], W Raffelsberger^[2], O Poch^[2], M Delorenzi^[3], G van der Pluijm^[4], GN Thalmann^[1], MG Cecchini^[1]

^[1]Department of Urology and Department of Clinical Research, University of Bern, Bern, Switzerland; ^[2]Department of Structural Biology and Genomics, Institute of Genetics and Molecular and Cellular Biology, Illkirch-Strasbourg, France; ^[3]Bioinformatic Core Facility, Swiss Institute of Bioinformatics, Lausanne, Switzerland; ^[4]Department of Urology, Leiden University Medical Center, Leiden, The Netherlands

P-60

COMBINATION VS SINGLE AGENT TREATMENT: THE EFFECTS OF ZOLEDRONIC ACID +/- DOXORUBICIN ON BREAST TUMOUR GROWTH IN BONE PRIOR TO DEVELOPMENT OF OSTEOLYTIC BONE DISEASE

HK Brown, PD Ottewell, CA Evans, RE Coleman, I Holen
Oncology, University of Sheffield, Sheffield, UK

P-61

CPG-ODN INHIBITS SMAD-DEPENDENT BMP SIGNALING; EFFECTS ON MYELOMA CELLS APOPTOSIS AND IN VITRO OSTEOBLASTOGENESIS

N Nørgaard^[1], T Holien^[1], S Jönsson^[2], H Hella^[1], T Espevik^[1], A Sundan^[1], T Standal^[1]

^[1]Department of cancer research and molecular medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway; ^[2]Section of Hematology, Department of Internal medicine, Sahlgrenska University Hospital, Gothenburg, Sweden

P-62

FIRST EVIDENCE FOR ANTI-TUMOUR EFFECTS OF DOXORUBICIN AND ZOLEDRONIC ACID FROM AN IMMUNOCOMPETENT MOUSE MODEL

PD Ottewell^[1], H Brown^[1], CA Evans^[1], NS Wind^[1], NJ Brown^[2], RE Coleman^[1], I Holen^[1]

^[1]Academic Unit of Clinical Oncology, University of Sheffield, Sheffield, UK; ^[2]Academic Unit of Surgical Oncology, University of Sheffield, Sheffield, UK

P-63

THE CAUSAL ROLE OF THE BMP SIGNALLING ANTAGONIST NOGGIN IN SUPPRESSING BONE FORMATION IN OSTEOLYTIC BONE METASTASIS

C Secondini, A Wetterwald, R Schwaninger, GN Thalmann, MG Cecchini

Department of Urology and Department of Clinical Research, University of Bern, Bern, Switzerland

P-64

AN EXOPOLYSACCHARIDE PRODUCED BY ALTEROMONAS INFERNUS REDUCES LUNG METASTASIS AND PROLONGS SURVIVAL RATE OF OSTEOSARCOMA-BEARING MICE

C Ruiz Velasco^[1], S Collic-Jouault^[2], C Siquin^[2], D Heymann^[1], M Padrines^[1]

^[1]INSERM U957, Université de Nantes, Nantes, France; ^[2]IFREMER, Laboratoire de biotechnologie et molécules marines, Nantes, France

P-65

MNNG-HOS OSTEOSARCOMA GROWTH IS ENHANCED BY HUMAN FAT AND ADIPOSE-DERIVED MESENCHYMAL STEM CELLS: IMPLICATION IN RECONSTRUCTIVE SURGERY FOLLOWING TUMOR TREATMENT

L Bourdais^[1,2], P Perrot^[1,2], D Duteille^[1,2], S Hervouet^[1,2], J Chesneau^[1,2], J Amiaud^[1,2], G Picarda^[1,2], G De Pigneux, F Redini^[1,2], D Heymann^[1,2], V Trichet^[1,2]

^[1]U957, INSERM, Nantes, France; ^[2]EA3822, University, Nantes, France; ^[3]EA3855, University, Tours, France

P-66

THE NOVEL AND SELECTIVE INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE INHIBITOR PQIP SUPPRESSES BONE CELL FUNCTION AND OSTEOCLAST-BREAST CANCER CELL CROSS-TALK IN VITRO

JG Logan^[1], E Landao-Bassonga^[1], VG Brunton^[2], AI Idris^[1]

^[1]Bone Research Group, Molecular Medicine Centre, Institute of Genetics and Molecular Medicine, Edinburgh, UK; ^[2]Division of Cancer Biology, Edinburgh Cancer Research Centre, Institute of Genetics & Molecular Medicine, Edinburgh, UK

P-67

INHIBITION OF DICKKOPF-1 (DKK-1) DELAYS PROSTATE CANCER GROWTH IN VIVO THROUGH INDUCTION OF P21CIP-1

CL Hall^[1], H Zhang^[1], S Baile^[1], S Kuhstoss^[2], ET Keller^[1]

^[1]Urology, University of Michigan, Ann Arbor, MI 48109, U.S.A.; ^[2]Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, U.S.A.

P-68

PERIPHERAL CANNABINOID TYPE 2 RECEPTOR REGULATES OSTEOCLAST FORMATION, MDA-MB-231 BREAST CANCER CELL MIGRATION AND BONE MARROW/TUMOUR CELL INTERACTION VIA PI3 KINASE/AKT AND P38 PATHWAYS

A Sophocleous, A Mackintosh, E Landao-Bassonga, SH Ralston, AI Idris

Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK

P-69

IDENTIFICATION OF HYDROGEN SULFIDE RELEASING COMPOUNDS AS NOVEL ANTIRESORPTIVE AND ANTITUMOUR AGENTS

AI Idris^[1], J Frantzias^[1], P Mollat^[2], A Sparatore^[3], P Del Soldato^[4], SH Ralston^[1]

^[1]Bone Research Group, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK; ^[2]Galapagos SASU, Romainville, France; ^[3]Department of Pharmaceutical Sciences "P. Pratesi", Università degli Studi di Milano, Milano, Italy.; ^[4]CTG Pharma S.r.l, Milano, Italy

P-70

DOES DIFFERENTIAL EXPRESSION OF CD151 AFFECT THE ABILITY OF BEAST CANCER CELLS TO ESTABLISH TUMOURS IN BONE?

NS Wind^[1], H Brown^[1], PD Ottewell^[1], R Sadej^[2], H Romanska^[2], F Berditchevski^[2], I Holen^[1]

^[1]Academic Unit of Oncology, University of Sheffield, Sheffield, UK; ^[2]School of Cancer Sciences, University of Birmingham, Birmingham, UK

P-71

GLPG0187 INHIBITS PROGRESSION OF ESTABLISHED BONE METASTASIS AND ACHIEVES MAXIMUM EFFICACY WHEN COMBINED WITH STANDARD-OF-CARE METASTATIC BREAST CANCER TREATMENTS

P Clément-Lacroix^[1], E Berrocal^[1], B Heckmann^[2], P Wigerinck^[3], G Lorenzon^[4], P Pujuguet^[1]
^[1]In vivo pharmacology, Galapagos SAS, Romainville, France; ^[2]Medicinal Chemistry, Galapagos SAS, Romainville, France; ^[3]Development, Galapagos NV, Mechelen, Belgium; ^[4]Development, Galapagos SAS, Romainville, France

P-72

THE HOMING OF PROSTATE CANCER TO BONE IN VIVO IS MODULATED BY ZOLEDRONIC ACID

KJ Reeves^[1,2], MG Cecchini^[3], G van der Pluijm^[4], CL Eaton^[2], FC Hamdy^[5], NJ Brown^[1]
^[1]Academic Unit of Surgical Oncology, University of Sheffield, Sheffield, UK; ^[2]Academic Unit of Bone Biology, University of Sheffield, Sheffield, UK; ^[3]Urology Research Laboratory, University of Bern, Bern, Switzerland; ^[4]Department of Urology, Leiden University Medical Center, Leiden, The Netherlands; ^[5]Urology & Oncology, University of Oxford, Oxford, UK

P-73

PROBING THE RELATIONSHIP BETWEEN BREAST CANCER STEM CELLS AND BONE METASTASIS

K Tan-Allen^[1], JE Gilmore^[1], J Foley^[1,2]
^[1]Medical Sciences, Indiana University, Bloomington, USA; ^[2]Cancer Center, Indiana University, Indianapolis, USA

P-74

ZOLEDRONIC ACID INDUCES IPP ACCUMULATION AND RELEASE FROM HUMAN CANCER CELLS, WHICH ACTIVATES V γ 9 δ 2 T CELL-DIFFERENTIATION AND MIGRATION IN VITRO AND MEDIATES V γ 9 δ 2 T CELL-INDUCED CANCER CELL DEATH IN VIVO

I Benzaid^[1], H Monkkonen^[2], V Stresing^[1], E Bonnelye^[1], J Green^[3], J Monkkonen^[2], P Clezardin^[1]
^[1]Faculty Of Medecin, INSERM UMR664, Lyon, France; ^[2]School Of Pharmacy, University Of Eastern Finland, Kuopio, Finland; ^[3]Novartis Institutes For Biomedical Research, Basel, Switzerland

P-75

SPONTANEOUS FUSION BETWEEN PROSTATE CANCER CELLS: A DRIVER FOR DEVELOPMENT OF TUMOR HETEROGENEITY AND GROWTH IN BONE

G Pesce, A Glen, J Lippitt, A Fowles, I Rehman, CL Eaton
Dept. Human Metabolism, University of Sheffield, Sheffield, UK

P-76

CORNING OSTEO ASSAY SURFACE FOR THE STUDY OF BONE RESORPTION

AF Faruqi, H Rao, J Causer, J Beltzer
Corning Life Sciences, Corning Inc., Corning, NY, USA

P-77

A NEW B CROSSLAPS® (CTX-I) ASSAY ON THE IDS-ISYS AUTOMATED ANALYSER

Z Seres, S Middlemist, C Dixon, D Laurie, A.K. Barnes, M Garrity
R & D, IDS Ltd., Boldon, UK

P-78

TWIST 1 EXPRESSION IN AN OSTEOTROPIC BREAST CANCER CELL LINE PROMOTES BONE METASTASIS FORMATION IN MOUSE.

M Croset^[1], D Goëhrig^[1], E Bonnelye^[1], S Ansieau^[2], A Puisieux^[2], P Clézardin^[1]

^[1]INSERM U664 Faculté Laennec, INSERM, Lyon, France; ^[2]INSERM U590 Centre Léon Bérard, INSERM, Lyon, France

P-79

THE ROLE OF PARATHYROID HORMONE-RELATED PROTEIN IN GIANT CELL TUMOUR OF BONE

RW Cowan^[1,3], G Singh^[1,3], M Ghert^[2,3]

^[1]Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada;

^[2]Department of Surgery, McMaster University, Hamilton, ON, Canada; ^[3]Juravinski Cancer Centre, Hamilton, ON, Canada

P-80

OSTEOCYTE-DERIVED FGF23 ACTIVATES EGR-1 SIGNALING IN PROSTATE CANCER CELLS: A NEW VICIOUS CYCLE IN BONE METASTASES

P Fournier^[1], D Edwards^[1], K White^[2], JM Chirgwin^[1]

^[1]Medicine, Indiana University, Indianapolis, USA; ^[2]Medical Genetics, Indiana University, Indianapolis, USA

P-81

INHIBITION OF DISCOIDIN DOMAIN RECEPTOR-1 (DDR1) IMPAIRS TUMOR-INDUCED OSTEOCLASTOGENESIS PREVENTING BONE METASTATIC HOMING AND COLONIZATION

K Valencia, C Zandueta, C Ormazábal, D Luis-Ravelo, I Antón, S Martínez, F Lecanda

Division of Oncology, University of Navarra, Center for Applied Medical Research, Pamplona, Spain

P-82

OSTEOPOROTIC CHANGES IN A RAT MODEL WITH EXPERIMENTAL LIVER FIBROSIS

X Ma^[1], SC Wang^[2], XD Ma^[3], J Wang^[4], MY Liu^[2]

^[1]Department of Orthopaedics, the First Affiliated Hospital of Medical School, Xi'an Jiaotong University, Xi'an 710061, China; ^[2]Department of Pharmaceutical Sciences, Xijing Hospital, the Fourth Military Medical University, Xi'an 710032, China; ^[3]Department of Gynaecology and Obstetrics, Xijing Hospital, the Fourth Military Medical University, Xi'an 710032, China; ^[4]Institute of Orthopaedic Surgery, Xijing Hospital, the Fourth Military Medical University, Xi'an 710032, China

P-83

A METHOD TO FOLLOW TUMOR GROWTH AND TUMOR INDUCED BONE LOSS SIMULTANEOUSLY OVER TIME, IN VIVO, USING WHOLE BODY BIOLUMINESCENCE FLUORESCENCE IMAGING

TJA Snoeks^[1], A Khmelinskii^[2], I Que^[1], B Lelieveldt^[2], EL Kaijzel^[1], CWGM Löwik^[1]

^[1]Endocrinology and Metabolic Diseases, LUMC, Leiden, The Netherlands; ^[2]LKEB - Image Processing, LUMC, Leiden, The Netherlands

P-84

RAP-661 TREATMENT, AN ALK3 (BMPRIA) ANTAGONIST, DECREASES RANKL AND REGULATES OSTEOCLASTOGENESIS.

N Solban^[1], M Cornwall-Brady^[1], Y Kawamoto^[1], KW Underwood^[1], R Kumar^[1], J Seehra^[1], E Canalis^[2], RS Pearsall

^[1]Preclinical, Acceleron Pharma, Cambridge, MA, USA; ^[2]Department of Research, St. Francis Hospital & Medical Center, Hartford, CT, USA

P-85

THE ROLE OF FIBRONECTIN ORIGINATING FROM DIFFERENT SOURCES ON BREAST CANCER METASTASIS DEVELOPMENT AND BONE REMODELING

A von Au^[1], M Vasel^[1], M Cecchini^[2], IA Nakchbandi^[1]

^[1]University of Heidelberg and, Max-Planck Institut for Biochemistry, Heidelberg, Germany;

^[2]Department of Urology, University of Bern, Bern, Switzerland

P-86

DEVELOPMENT OF A TARGETED STRATEGY FOR ENRICHMENT AND DETECTION OF CALCIUM BINDING PROTEINS AS POTENTIAL BIOMARKERS FOR BONE METASTASES IN BREAST CANCER

SL Wood, JA Westbrook, J Peng, PJ Selby, JE Brown

Cancer Research UK Clinical Centre, St James's University Hospital, Leeds, UK.

P-87

CATHEPSIN K INHIBITORS FOR THE TREATMENT OF BONE METASTASIS

E Lindström^[1], L Vrang^[1], S Sedig^[1], Y Terelius^[1], B-L Sahlberg^[1], K Wikström^[1], B Samuelsson^[1], T Chambers^[2], U Grabowska^[3]

^[1]Discovery Research, Medivir, Huddinge, Sweden; ^[2]Department of Cellular Pathology, St George's, University of London, London, UK; ^[3]Discovery Research, Medivir, Little Chesterford, UK

P-88

VERY LATE ANTIGEN-4 (VLA-4) AS AN IMAGING TARGET FOR MULTIPLE MYELOMA AND PRE-METASTATIC NICHE

M Shokeen^[1], A Zheleznyak^[1], JM Wilson^[1], K Nguyen^[1], R Liu^[2], L Collins^[3], R Ferdani^[1], M Jiang^[1], JK Schwarz^[4], KN Weilbaecher^[5], MH Tomasson^[5], D Piwnica-Worms^[3], KS Lam^[2], CJ Anderson^[1]

^[1]Radiological Sciences, Washington University School of Medicine, Saint Louis, USA; ^[2]Division of Hematology and Oncology, University of California-Davis Cancer Center, Davis, USA; ^[3]Molecular Imaging Center, Washington University School of Medicine, Saint Louis, USA; ^[4]Radiation Oncology, Washington University School of Medicine, Saint Louis, USA; ^[5]Department of Medicine, Washington University School of Medicine, Saint Louis, USA

P-89

EVALUATION OF A NOVEL BONE TARGETED ARACYTIDINE THERAPY IN DOGS WITH SPONTANEOUS OSTEOSARCOMA.

S Zinnen^[1], D Thamm^[2], D Vail^[3], T Fan^[4], A Karpeisky^[1]

^[1]Research and Development, MBC Pharma Inc, Aurora, CO, USA; ^[2]Oncology at the Animal Cancer Center, Colorado State University, Fort Collins, CO, USA; ^[3]School of Veterinary Medicine, University of Wisconsin, Madison, WI, USA; ^[4]Veterinary Clinical Medicine, University of Illinois, Urbana, IL, USA

P-90

GROWTH INHIBITION OF HUMAN PRIMARY BREAST CANCER CELL LINE BY ARSENIC AND EFFECT OF ARSENIC AND LEAD ON HUMAN MESENCHYMAL STEM CELLS AND DIFFERENTIATION OF MSCS INTO OSTEOBLASTS

Aftab Chattha^[1], A.R. Shakoori^[1]

^[1]School of Biological Sciences, University of the Punjab, Lahore, Pakistan; ^[2]School of Biological Sciences, University of the Punjab, Lahore, Pakistan